Ocular Therapeutix (OCUL) Share-based Compensation (2013 - 2026)

Ocular Therapeutix's Share-based Compensation history runs 14 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 75.98% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $31.5 million, a 2.32% decrease from a year earlier, with the FY2025 full-year figure at $79.4 million, up 47.6% from the prior year.
• Share-based Compensation retreated to $2.5 million in Q1 2026 per OCUL's latest filing, from $11.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $91.9 million in Q2 2025 and bottomed at $2.5 million in Q1 2026.
• The 5-year median for Share-based Compensation is $4.6 million (2023), against an average of $17.7 million.
• Across the five-year window, Share-based Compensation jumped 1175.0% in 2025 and plunged 75.98% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $4.2 million in 2022, then increased by 2.22% to $4.3 million in 2023, then surged by 66.29% to $7.2 million in 2024, then surged by 57.83% to $11.4 million in 2025, then plunged by 77.89% to $2.5 million in 2026.
• Per Business Quant, the three latest OCUL Share-based Compensation figures stand at $2.5 million (Q1 2026), $11.4 million (Q4 2025), and $84.7 million (Q3 2025).